Tetracyclines: what a rheumatologist needs to know?
Identifieur interne : 001793 ( Istex/Corpus ); précédent : 001792; suivant : 001794Tetracyclines: what a rheumatologist needs to know?
Auteurs : Suzan M. AttarSource :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2009-07.
English descriptors
- Teeft :
- Antibiotic, Arthritis, Arthritis rheum, Blood vessel formation, Bone formation, Bone metabolism, Calcinosis, Calcinosis deposit, Calcinosis size, Chronic reactive, Complete response, Cutaneous, Cutaneous calcinosis, Cutaneous sarcoidosis, Disease activity, Disease duration, Doxycycline, Doxycycline group, Endothelial cells, Functional status, Greater improvement, International journal, Intravenous doxycycline, Minocycline, Nitric oxide synthetase, Oral doxycycline, Partial response, Placebo, Placebo group, Primary outcome, Propionibacterium acnes, Randomized, Relevant articles, Rheum, Rheumatic, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatologist, Sarcoidosis, Saudi arabia, Seronegative arthritis, Seronegative spondyloarthritis, Skin hyperpigmentation, Skin lesions, Systemic sclerosis, Tetracycline, Undifferentiated spondyloarthropathy.
Abstract
Tetracyclines are broad‐spectrum antibiotics that act at the ribosomal level. They were first introduced in 1948 and were widely prescribed by dermatologists in the early 1950s for treatment of acne. More recently, biologic actions of tetracyclines affecting inflammation, angiogenesis, and bone metabolism have been researched. The therapeutic effects of tetracycline and its analogues in rheumatic diseases have also been investigated. This article will review the rheumatological use of tetracycline and its analogues.
Url:
DOI: 10.1111/j.1756-185X.2009.01389.x
Links to Exploration step
ISTEX:DD1C98B17705F3B99DE713CD07D619DEBA850774Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tetracyclines: what a rheumatologist needs to know?</title><author><name sortKey="Attar, Suzan M" sort="Attar, Suzan M" uniqKey="Attar S" first="Suzan M." last="Attar">Suzan M. Attar</name><affiliation><mods:affiliation>Department of Medicine, King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DD1C98B17705F3B99DE713CD07D619DEBA850774</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1756-185X.2009.01389.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-BPXDG31X-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001793</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001793</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Tetracyclines: what a rheumatologist needs to know?</title><author><name sortKey="Attar, Suzan M" sort="Attar, Suzan M" uniqKey="Attar S" first="Suzan M." last="Attar">Suzan M. Attar</name><affiliation><mods:affiliation>Department of Medicine, King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">12</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="84">84</biblScope><biblScope unit="page" to="89">89</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2009-07">2009-07</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antibiotic</term><term>Arthritis</term><term>Arthritis rheum</term><term>Blood vessel formation</term><term>Bone formation</term><term>Bone metabolism</term><term>Calcinosis</term><term>Calcinosis deposit</term><term>Calcinosis size</term><term>Chronic reactive</term><term>Complete response</term><term>Cutaneous</term><term>Cutaneous calcinosis</term><term>Cutaneous sarcoidosis</term><term>Disease activity</term><term>Disease duration</term><term>Doxycycline</term><term>Doxycycline group</term><term>Endothelial cells</term><term>Functional status</term><term>Greater improvement</term><term>International journal</term><term>Intravenous doxycycline</term><term>Minocycline</term><term>Nitric oxide synthetase</term><term>Oral doxycycline</term><term>Partial response</term><term>Placebo</term><term>Placebo group</term><term>Primary outcome</term><term>Propionibacterium acnes</term><term>Randomized</term><term>Relevant articles</term><term>Rheum</term><term>Rheumatic</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatologist</term><term>Sarcoidosis</term><term>Saudi arabia</term><term>Seronegative arthritis</term><term>Seronegative spondyloarthritis</term><term>Skin hyperpigmentation</term><term>Skin lesions</term><term>Systemic sclerosis</term><term>Tetracycline</term><term>Undifferentiated spondyloarthropathy</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tetracyclines are broad‐spectrum antibiotics that act at the ribosomal level. They were first introduced in 1948 and were widely prescribed by dermatologists in the early 1950s for treatment of acne. More recently, biologic actions of tetracyclines affecting inflammation, angiogenesis, and bone metabolism have been researched. The therapeutic effects of tetracycline and its analogues in rheumatic diseases have also been investigated. This article will review the rheumatological use of tetracycline and its analogues.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>doxycycline</json:string><json:string>tetracycline</json:string><json:string>minocycline</json:string><json:string>placebo</json:string><json:string>calcinosis</json:string><json:string>randomized</json:string><json:string>sarcoidosis</json:string><json:string>rheumatoid</json:string><json:string>rheumatic diseases</json:string><json:string>rheumatoid arthritis</json:string><json:string>rheumatologist</json:string><json:string>cutaneous</json:string><json:string>arthritis rheum</json:string><json:string>doxycycline group</json:string><json:string>international journal</json:string><json:string>arthritis</json:string><json:string>antibiotic</json:string><json:string>rheum</json:string><json:string>disease duration</json:string><json:string>systemic sclerosis</json:string><json:string>calcinosis deposit</json:string><json:string>undifferentiated spondyloarthropathy</json:string><json:string>rheumatic</json:string><json:string>endothelial cells</json:string><json:string>greater improvement</json:string><json:string>disease activity</json:string><json:string>relevant articles</json:string><json:string>skin hyperpigmentation</json:string><json:string>bone metabolism</json:string><json:string>intravenous doxycycline</json:string><json:string>oral doxycycline</json:string><json:string>primary outcome</json:string><json:string>nitric oxide synthetase</json:string><json:string>saudi arabia</json:string><json:string>cutaneous sarcoidosis</json:string><json:string>complete response</json:string><json:string>partial response</json:string><json:string>skin lesions</json:string><json:string>blood vessel formation</json:string><json:string>calcinosis size</json:string><json:string>bone formation</json:string><json:string>seronegative spondyloarthritis</json:string><json:string>chronic reactive</json:string><json:string>functional status</json:string><json:string>seronegative arthritis</json:string><json:string>propionibacterium acnes</json:string><json:string>cutaneous calcinosis</json:string><json:string>placebo group</json:string></teeft></keywords><author><json:item><name>Suzan M. ATTAR</name><affiliations><json:string>Department of Medicine, King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>calcinosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>osteoarthritis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rheumatoid arthritis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>sarcoidosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tetracyclines</value></json:item></subject><articleId><json:string>APL1389</json:string></articleId><arkIstex>ark:/67375/WNG-BPXDG31X-H</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Tetracyclines are broad‐spectrum antibiotics that act at the ribosomal level. They were first introduced in 1948 and were widely prescribed by dermatologists in the early 1950s for treatment of acne. More recently, biologic actions of tetracyclines affecting inflammation, angiogenesis, and bone metabolism have been researched. The therapeutic effects of tetracycline and its analogues in rheumatic diseases have also been investigated. This article will review the rheumatological use of tetracycline and its analogues.</abstract><qualityIndicators><score>6.225</score><pdfWordCount>3361</pdfWordCount><pdfCharCount>22471</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>595.206 x 779.408 pts</pdfPageSize><pdfWordsPerPage>560</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>72</abstractWordCount><abstractCharCount>521</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Tetracyclines: what a rheumatologist needs to know?</title><pmid><json:string>20374324</json:string></pmid><genre><json:string>review-article</json:string></genre><host><title>International Journal of Rheumatic Diseases</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1756-185X</json:string></doi><issn><json:string>1756-1841</json:string></issn><eissn><json:string>1756-185X</json:string></eissn><publisherId><json:string>APL</json:string></publisherId><volume>12</volume><issue>2</issue><pages><first>84</first><last>89</last><total>6</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2009</json:string><json:string>1950s</json:string><json:string>2006</json:string><json:string>1994</json:string><json:string>1972</json:string><json:string>1948</json:string><json:string>1966</json:string><json:string>1995</json:string><json:string>1967</json:string></date><geogName></geogName><orgName><json:string>National Library of Medicine, NLM</json:string><json:string>King Abdul-Aziz University Hospital, PO Box</json:string><json:string>KAUH</json:string><json:string>Saudi Arabia Abstract Tetracyclines</json:string><json:string>King Abdul-Aziz University</json:string><json:string>American College of Rheumatology</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Our</json:string><json:string>Asia Paci</json:string><json:string>Results</json:string><json:string>Rheumatology</json:string><json:string>ProfessorDepartment</json:string><json:string>S. M. Attar</json:string></persName><placeName><json:string>Jeddah</json:string><json:string>Saudi Arabia</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Stone et al.</json:string><json:string>Tilley et al.</json:string><json:string>Kloppenburg et al.</json:string><json:string>Dell et al.</json:string><json:string>Brandt et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-BPXDG31X-H</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1111/j.1756-185X.2009.01389.x</json:string></doi><id>DD1C98B17705F3B99DE713CD07D619DEBA850774</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-BPXDG31X-H/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-BPXDG31X-H/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-BPXDG31X-H/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Tetracyclines: what a rheumatologist needs to know?</title><title level="a" type="short">Tetracyclines, what a rheumatologist needs to know?</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><availability><licence>© 2009 Asia Pacific League of Associations for Rheumatology</licence></availability><date type="published" when="2009-07"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">Tetracyclines: what a rheumatologist needs to know?</title><title level="a" type="short">Tetracyclines, what a rheumatologist needs to know?</title><author xml:id="author-0000"><persName><forename type="first">Suzan M.</forename><surname>ATTAR</surname></persName><affiliation><orgName type="division">Department of Medicine</orgName><orgName type="institution">King Abdulaziz University Hospital (KAUH)</orgName><address><addrLine>Jeddah</addrLine><addrLine>Saudi Arabia</addrLine><country key="SA" xml:lang="en">SAUDI ARABIA</country></address></affiliation></author><idno type="istex">DD1C98B17705F3B99DE713CD07D619DEBA850774</idno><idno type="ark">ark:/67375/WNG-BPXDG31X-H</idno><idno type="DOI">10.1111/j.1756-185X.2009.01389.x</idno><idno type="unit">APL1389</idno><idno type="toTypesetVersion">file:APL.APL1389.pdf</idno></analytic><monogr><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="pISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><idno type="book-DOI">10.1111/(ISSN)1756-185X</idno><idno type="book-part-DOI">10.1111/apl.2009.12.issue-2</idno><idno type="product">APL</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">12</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="84">84</biblScope><biblScope unit="page" to="89">89</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2009-07"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>Tetracyclines are broad‐spectrum antibiotics that act at the ribosomal level. They were first introduced in 1948 and were widely prescribed by dermatologists in the early 1950s for treatment of acne. More recently, biologic actions of tetracyclines affecting inflammation, angiogenesis, and bone metabolism have been researched. The therapeutic effects of tetracycline and its analogues in rheumatic diseases have also been investigated. This article will review the rheumatological use of tetracycline and its analogues.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">calcinosis</term><term xml:id="k2">osteoarthritis</term><term xml:id="k3">rheumatoid arthritis</term><term xml:id="k4">sarcoidosis</term><term xml:id="k5">tetracyclines</term></keywords><keywords rend="tocHeading1"><term>Review article</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-BPXDG31X-H/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Asia</publisherName><publisherLoc>Melbourne, Australia</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1756-185X</doi><issn type="print">1756-1841</issn><issn type="electronic">1756-185X</issn><idGroup><id type="product" value="APL"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES">International Journal of Rheumatic Diseases</title></titleGroup></publicationMeta><publicationMeta level="part" position="07002"><doi origin="wiley">10.1111/apl.2009.12.issue-2</doi><numberingGroup><numbering type="journalVolume" number="12">12</numbering><numbering type="journalIssue" number="2">2</numbering></numberingGroup><coverDate startDate="2009-07">July 2009</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="2" status="forIssue"><doi origin="wiley">10.1111/j.1756-185X.2009.01389.x</doi><idGroup><id type="unit" value="APL1389"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="tocHeading1">Review article</title></titleGroup><copyright>© 2009 Asia Pacific League of Associations for Rheumatology</copyright><eventGroup><event type="firstOnline" date="2009-07-16"></event><event type="publishedOnlineFinalForm" date="2009-07-16"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText" date="2010-04-08"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-04"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-24"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="84">84</numbering><numbering type="pageLast" number="89">89</numbering></numberingGroup><correspondenceTo>
: S. M. Attar, MBBCH, FAVR, FRCPC, FRCPC (Rheum), Assistant ProfessorDepartment Of Internal Medicine.King Abdul‐Aziz University, Consultant Rheumatology & Internal Medicine‐ King Abdul‐Aziz University Hospital, PO Box 80215 Jeddah 21589, Kingdome of Saudi Arabia. Email: <email>suzan_attar@hotmail.com</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:APL.APL1389.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="4"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="3170"></count></countGroup><titleGroup><title type="main">Tetracyclines: what a rheumatologist needs to know?</title><title type="shortAuthors">S. M. Attar</title><title type="short">Tetracyclines, what a rheumatologist needs to know?</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#aff-1-1"><personName><givenNames>Suzan M.</givenNames><familyName>ATTAR</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="aff-1-1" countryCode="SA"><unparsedAffiliation>Department of Medicine, King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">calcinosis</keyword><keyword xml:id="k2">osteoarthritis</keyword><keyword xml:id="k3">rheumatoid arthritis</keyword><keyword xml:id="k4">sarcoidosis</keyword><keyword xml:id="k5">tetracyclines</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Tetracyclines are broad‐spectrum antibiotics that act at the ribosomal level. They were first introduced in 1948 and were widely prescribed by dermatologists in the early 1950s for treatment of acne. More recently, biologic actions of tetracyclines affecting inflammation, angiogenesis, and bone metabolism have been researched. The therapeutic effects of tetracycline and its analogues in rheumatic diseases have also been investigated. This article will review the rheumatological use of tetracycline and its analogues.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Tetracyclines: what a rheumatologist needs to know?</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Tetracyclines, what a rheumatologist needs to know?</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Tetracyclines: what a rheumatologist needs to know?</title></titleInfo><name type="personal"><namePart type="given">Suzan M.</namePart><namePart type="family">ATTAR</namePart><affiliation>Department of Medicine, King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Blackwell Publishing Asia</publisher><place><placeTerm type="text">Melbourne, Australia</placeTerm></place><dateIssued encoding="w3cdtf">2009-07</dateIssued><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">4</extent><extent unit="formulas">0</extent><extent unit="references">24</extent><extent unit="words">3170</extent></physicalDescription><abstract lang="en">Tetracyclines are broad‐spectrum antibiotics that act at the ribosomal level. They were first introduced in 1948 and were widely prescribed by dermatologists in the early 1950s for treatment of acne. More recently, biologic actions of tetracyclines affecting inflammation, angiogenesis, and bone metabolism have been researched. The therapeutic effects of tetracycline and its analogues in rheumatic diseases have also been investigated. This article will review the rheumatological use of tetracycline and its analogues.</abstract><subject lang="en"><genre>keywords</genre><topic>calcinosis</topic><topic>osteoarthritis</topic><topic>rheumatoid arthritis</topic><topic>sarcoidosis</topic><topic>tetracyclines</topic></subject><relatedItem type="host"><titleInfo><title>International Journal of Rheumatic Diseases</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1756-1841</identifier><identifier type="eISSN">1756-185X</identifier><identifier type="DOI">10.1111/(ISSN)1756-185X</identifier><identifier type="PublisherID">APL</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>84</start><end>89</end><total>6</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Delayed effusive pericarditis and recurrent pleural effusion after radiation treatment for Hodgkin's disease responsive to per os doxycycline</title></titleInfo><name type="personal"><namePart type="given">KN</namePart><namePart type="family">Fragoulis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Handrinou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Papadopoulos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Dardoufas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Falagas</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fragoulis KN, Handrinou E, Papadopoulos V, Dardoufas K, Falagas ME (2006) Delayed effusive pericarditis and recurrent pleural effusion after radiation treatment for Hodgkin's disease responsive to per os doxycycline. Eur J Haematol 76, 176–9.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>176</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Haematol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>176</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Dose–response effect of tetracyclines on cerebral matrix metalloproteinase‐9 after vascular endothelial growth factor</title></titleInfo><name type="personal"><namePart type="given">CZ</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Yao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lee CZ, Yao JS, Huang Y, et al . (2006) Dose–response effect of tetracyclines on cerebral matrix metalloproteinase‐9 after vascular endothelial growth factor. Cerebral Blood Flow Metabolism 26, 1157–64.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>1157</start><end>64</end></extent></part><relatedItem type="host"><titleInfo><title>Cerebral Blood Flow Metabolism</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>1157</start><end>64</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Katzung BG (2004) Basic Clinical Pharmacology, 9th edn. pp. 755–8. McGraw‐Hill.</title></titleInfo><note type="citation/reference">Katzung BG (2004) Basic Clinical Pharmacology, 9th edn. pp. 755–8. McGraw‐Hill.</note><name type="personal"><namePart type="given">BG</namePart><namePart type="family">Katzung</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book</genre><originInfo><publisher>McGraw‐Hill</publisher></originInfo><part><date>2004</date><extent unit="pages"><start>755</start><end>8</end></extent></part></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Safety of doxycycline and minocycline: a systematic review</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JJ</namePart><namePart type="family">Leyden</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Smith K, Leyden JJ (2005) Safety of doxycycline and minocycline: a systematic review. Clin Ther 27, 1329–42.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1329</start><end>42</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1329</start><end>42</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Tetracyclines: nonantibiotic properties and their clinical implications</title></titleInfo><name type="personal"><namePart type="given">AN</namePart><namePart type="family">Sapadin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Fleischmajer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54, 258–65. Review.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>258</start><end>65</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>258</start><end>65</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Antibiotics</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Alarcon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><originInfo><publisher>Mosby</publisher></originInfo><part><date>2003</date><extent unit="pages"><start>491</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>A novel mechanism of action of tetracyclines effect of nitric oxide synthetase</title></titleInfo><name type="personal"><namePart type="given">AR</namePart><namePart type="family">Amin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MG</namePart><namePart type="family">Attur</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GD</namePart><namePart type="family">Thakker</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Amin AR, Attur MG, Thakker GD, et al . (1996) A novel mechanism of action of tetracyclines effect of nitric oxide synthetase. Proc Natl Acad Sci USA 93, 1401–9.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>1401</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci USA</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>1401</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Tigecycline: a review of a new glycylcycline antibiotic</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Scheinfeld</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Scheinfeld N (2005) Tigecycline: a review of a new glycylcycline antibiotic. J Dermatolog Treat 16, 207–12.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>207</start><end>12</end></extent></part><relatedItem type="host"><titleInfo><title>J Dermatolog Treat</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>207</start><end>12</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Should tetracycline treatment be used more extensively for rheumatoid arthritis</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Stone</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PR</namePart><namePart type="family">Fortin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Pacheco‐Tena</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RD</namePart><namePart type="family">Inman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stone M, Fortin PR, Pacheco‐Tena C, Inman RD (2003) Should tetracycline treatment be used more extensively for rheumatoid arthritis. J Rheumatol 30, 2112–22.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>2112</start><end>22</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>2112</start><end>22</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Minocycline in active rheumatoid arthritis. A double blind, placebo‐controlled trial</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Kloppenburg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FC</namePart><namePart type="family">Breedveld</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Terwiel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Mallee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BA</namePart><namePart type="family">Dijkmans</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA (1994) Minocycline in active rheumatoid arthritis. A double blind, placebo‐controlled trial. Arthritis Rheum 37, 629–36.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>629</start><end>36</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>629</start><end>36</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Minocycline in rheumatoid arthritis. A 48‐week, double blind, placebo‐controlled trial</title></titleInfo><name type="personal"><namePart type="given">BC</namePart><namePart type="family">Tilley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GS</namePart><namePart type="family">Alarcon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SP</namePart><namePart type="family">Heyse</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DO</namePart><namePart type="family">Clegg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GS</namePart><namePart type="family">Alarcon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tilley BC, Alarcon GS, Heyse SP, Li S, Clegg DO, Alarcon GS (1995) Minocycline in rheumatoid arthritis. A 48‐week, double blind, placebo‐controlled trial. MIRA Trial Group Ann Intern Med 122, 81–9.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><extent unit="pages"><start>81</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>MIRA Trial Group Ann Intern Med</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><extent unit="pages"><start>81</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double blind, placebo‐controlled trial</title></titleInfo><name type="personal"><namePart type="given">JR</namePart><namePart type="family">O'Dell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CE</namePart><namePart type="family">Haire</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Palmer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">O'Dell JR, Haire CE, Palmer W, et al . (1997) Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double blind, placebo‐controlled trial. Arthritis Rheum 40, 842–8.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>842</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>842</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Treatment of early sero‐positive rheumatoid arthritis: a two‐year, double‐blind comparison of minocycline and hydroxychloroquine</title></titleInfo><name type="personal"><namePart type="given">JR</namePart><namePart type="family">O'Dell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KW</namePart><namePart type="family">Blakely</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Mallek</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">O'Dell JR, Blakely KW, Mallek JA, et al . (2001) Treatment of early sero‐positive rheumatoid arthritis: a two‐year, double‐blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 44, 2235–41.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>2235</start><end>41</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>2235</start><end>41</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone</title></titleInfo><name type="personal"><namePart type="given">JR</namePart><namePart type="family">O'Dell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JR</namePart><namePart type="family">Elliott</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Mallek</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">O'Dell JR, Elliott JR, Mallek JA, et al . (2006) Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum 54, 621–7.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>621</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>621</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double blind, placebo‐controlled trial</title></titleInfo><name type="personal"><namePart type="given">EW</namePart><namePart type="family">St Calir</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WE</namePart><namePart type="family">Wilkinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DS</namePart><namePart type="family">Pisetsky</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">St Calir EW, Wilkinson WE, Pisetsky DS, et al . (2001) The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double blind, placebo‐controlled trial. Arthritis Rheum 44, 1043–7.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1043</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1043</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Pilot clinical trial of intravenous doxycycline versus placebo for rheumatoid arthritis</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Pillemer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Gulko</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ligier</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pillemer S, Gulko P, Ligier S, et al . (2003) Pilot clinical trial of intravenous doxycycline versus placebo for rheumatoid arthritis. J Rheumatol 30, 41–3.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>41</start><end>3</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>41</start><end>3</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Effects of Doxycycline on progression of osteoarthritis: results of a RCT, double‐blind trial</title></titleInfo><name type="personal"><namePart type="given">KD</namePart><namePart type="family">Brandt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Mazzuca</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BP</namePart><namePart type="family">Katz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brandt KD, Mazzuca SA, Katz BP, et al . (2005) Effects of Doxycycline on progression of osteoarthritis: results of a RCT, double‐blind trial. Arthritis Rheum 52, 2015–25.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>2015</start><end>25</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>2015</start><end>25</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Viscosupplementation for the treatment of osteoarthritis of the knee</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Bellamy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Campbell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Robinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Gee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Bourne</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Wells</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 19, CD005321.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>CD005321</start></extent></part><relatedItem type="host"><titleInfo><title>Cochrane Database Syst Rev</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>CD005321</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>The use of tetracyclines for the treatment of sarcoidosis</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Bachelez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Senet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Cadranel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kaoukhov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LI</namePart><namePart type="family">Dubertret</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret LI (2001) The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137, 69–73.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>137</number></detail><extent unit="pages"><start>69</start><end>73</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>137</number></detail><extent unit="pages"><start>69</start><end>73</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>) Therapeutic options for sarcoidosis: new and old</title></titleInfo><name type="personal"><namePart type="given">RP</namePart><namePart type="family">Baughman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baughman RP (2002) Therapeutic options for sarcoidosis: new and old. Curr Opin Pulm Med 8, 464–9.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>464</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Pulm Med</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>464</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline</title></titleInfo><name type="personal"><namePart type="given">LP</namePart><namePart type="family">Robertson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RW</namePart><namePart type="family">Marshall</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Hickling</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Robertson LP, Marshall RW, Hickling P (2003) Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 62, 267–9.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>267</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>267</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Minocycline is not effective in systemic sclerosis: results of an open‐label multicenter trial</title></titleInfo><name type="personal"><namePart type="given">MD</namePart><namePart type="family">Mayes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">O'Donnell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NF</namePart><namePart type="family">Rothfield</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Csuka</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mayes MD, O'Donnell D, Rothfield NF, Csuka ME (2004) Minocycline is not effective in systemic sclerosis: results of an open‐label multicenter trial. Arthritis Rheum 50, 553–7.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>553</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>553</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Randomized, blinded, placebo controlled trial of doxycycline for chronic sero‐negative arthritis</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Smieja</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DW</namePart><namePart type="family">MacPherson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Kean</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Smieja M, MacPherson DW, Kean W, et al . (2001) Randomized, blinded, placebo controlled trial of doxycycline for chronic sero‐negative arthritis. Ann Rheumatic Dis 60, 1088–94.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1088</start><end>94</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheumatic Dis</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1088</start><end>94</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to chlamydia‐induced arthritis. A prospective, randomized 9‐month comparison</title></titleInfo><name type="personal"><namePart type="given">JD</namePart><namePart type="family">Carter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Valeriano</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FB</namePart><namePart type="family">Vasey</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carter JD, Valeriano J, Vasey FB (2004) Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to chlamydia‐induced arthritis. A prospective, randomized 9‐month comparison. J Rheumatol 31, 1973–80.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>1973</start><end>80</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>1973</start><end>80</end></extent></part></relatedItem></relatedItem><identifier type="istex">DD1C98B17705F3B99DE713CD07D619DEBA850774</identifier><identifier type="ark">ark:/67375/WNG-BPXDG31X-H</identifier><identifier type="DOI">10.1111/j.1756-185X.2009.01389.x</identifier><identifier type="ArticleID">APL1389</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2009 Asia Pacific League of Associations for Rheumatology</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-BPXDG31X-H/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001793 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001793 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:DD1C98B17705F3B99DE713CD07D619DEBA850774
|texte= Tetracyclines: what a rheumatologist needs to know?
}}
| This area was generated with Dilib version V0.6.33. |  |